Towards quantitative prediction of oral drug absorption

Clinical Pharmacokinetics

Volumn 47, Issue 10, 2008, Pages 655-667

  Dressman, Jennifer B ^a   Thelen, Kirstin ^a   Jantratid, Ekarat ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Absorption; Pharmacokinetic modelling

Indexed keywords

CIMETIDINE; DANAZOL; DIPYRIDAMOLE; EFAVIRENZ; EUDRAGIT; EXEMESTANE; GEFITINIB; GRISEOFULVIN; IVERMECTIN; KETOCONAZOLE; KETOPROFEN; MIDAZOLAM; NIFEDIPINE; NITRENDIPINE; PHENYTOIN; SPIRONOLACTONE;

CELL STRAIN CACO 2; COMPLEX FORMATION; COMPUTER MODEL; COMPUTER PROGRAM; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DECOMPOSITION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SOLUBILITY; FIRST PASS EFFECT; GRAPEFRUIT JUICE; HUMAN; LIPOPHILICITY; MEMBRANE PERMEABILITY; PARTITION COEFFICIENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY;

EID: 51649104303     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847100-00003     Document Type: Review

References (96)

1. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000; 11 Suppl. 2: S73-80
2. Dressman JB, Fleisher D. Mixing-tank model for predicting dissolution rate control or oral absorption. J Pharm Sci 1986; 75 (2): 109-16
3. US FDA Center for Evaluation and Research. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system [online]. Available from URL: http://www.fda.gov/cder/guidance/3618fnl.pdf [Accessed 2008 Feb 29]
4. Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15 (1): 11-22
5. Jantratid E, Janssen N, Reppas C, et al. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 2008; 25 (7): 1663-76
6. Vertzoni M, Dressman J, Butler J, et al. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm 2005; 60 (3): 413-7
7. Finholt P, Solvang S. Dissolution kinetics of drugs in human gastric juice: the role of surface tension. J Pharm Sci 1968; 57 (8): 1322-6
8. Macheras P, Koupparis M, Apostolleli E. Dissolution of 4 controlled-release theophylline formulations in milk. Int J Pharm 1987; 36: 73-9
9. Junginger HE, Verhoeven J, Peschier LJC. A new in vitro model to detect interactions between controlled release dosage forms and food. Acta Pharm Technol 1990; 36 (3): 155-60
10. Krämer J. Korrelation biopharmazeutischer in vivo und in vitro Daten von Theophyllin und Verapamil Retardpräparaten [PhD dissertation]. Heidelberg: Ruprecht-Karls-University, 1995
11. Dermentzoglou LC. Changes in upper gastrointestinal pH with aging: implications for drug absorption [PhD dissertation]. Ann Arbor (MI): University of Michigan, 1989
12. Lindahl A, Ungell AL, Knutson L, et al. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res 1997; 14 (4): 497-502
13. Kalantzi L, Goumas K, Kalioras V, et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/ bioequivalence studies. Pharm Res 2006; 23 (1): 165-76
14. Fordtran JS, Locklear TW. Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am J Dig Dis 1966; 11 (7): 503-21
15. Welling PG. Effects of food on drug absorption. Annu Rev Nutr 1996; 16: 383-415
16. Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 2008; 60: 717-33
17. Takano R, Sugano K, Higashida A, et al. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res 2006; 23 (6): 1144-56
18. Zangenberg NH, Müllertz A, Kristensen HG, et al. A dynamic in vitro lipolysis model: I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci 2001; 14 (2): 115-22
19. Zangenberg NH, Müllertz A, Kristensen HG, et al. A dynamic in vitro lipolysis model: II. Evaluation of the model. Eur J Pharm Sci 2001; 14 (3): 237-44
20. Fatouros DG, Müllertz A. Using in vitro dynamic lipolysis modeling as a tool for exploring IVIVC relationships for oral lipid-based formulations. In: Hauss DJ, editor. Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs. 1st ed. New York: Informa Healthcare USA, Inc., 2007: 257-72
21. Conners K, Amidon GL, Valentino JS. Chemical stability of pharmaceuticals: a handbook for pharmacists. 2nd ed. New York: Wiley & Sons, Inc., 1986
22. Becker C, Dressman JB, Amidon GL, et al. Biowaiver monographs for immediate release solid oral dosage forms: isoniazid. J Pharm Sci 2007; 96 (3): 522-31
23. Winiwarter S, Bonham NM, Ax F, et al. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters: a multivariate data analysis approach. J Med Chem 1998; 41 (25): 4939-49
24. Lennernäs H. Human intestinal permeability. J Pharm Sci 1998; 87 (4): 403-10
25. Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 2001; 44 (6): 923-30
26. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998; 41 (7): 1007-10
27. Sugano K, Hamada H, Machida M, et al. High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J Biomol Screen 2001; 6 (3): 189-96
28. Zhu C, Jiang L, Chen TM, et al. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 2002; 37 (5): 399-407
29. Avdeef A. The rise of PAMPA. Expert Opin Drug Metab Toxicol 2005; 1 (2): 325-42
30. Avdeef A, Bendels S, Di L, et al. PAMPA-critical factors for better predictions of absorption. J Pharm Sci 2007; 96 (11): 2893-909
31. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcino-ma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96 (3): 736-49
32. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001; 46 (1-3): 27-43
33. Alsenz J, Haenel E. Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm Res 2003; 20 (12): 1961-9
34. Ingels F, Beck B, Oth M, et al. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int J Pharm 2004; 274 (1-2): 221-32
35. Stewart BH, Chan OH, Lu RH, et al. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm Res 1995; 12 (5): 693-9
36. Chong S, Dando SA, Soucek KM, et al. In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res 1996; 13 (1): 120-3
37. Lennernäs H, Palm K, Fagerholm U, et al. Comparison between active and passive transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int J Pharm 1996; 127: 103-7
38. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man: fact or myth. Pharm Res 1997; 14 (6): 763-6
39. Collett A, Sims E, Walker D, et al. Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption. Pharm Res 1996; 13 (2): 216-21
40. Chiou WL, Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 1998; 15 (11): 1792-5
41. Chiou WL, Buehler PW. Comparison of oral absorption and bioavailablity of drugs between monkey and human. Pharm Res 2002; 19 (6): 868-74
42. Willmann S, Edginton AN, Dressman JB. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm Res 2007; 24 (7): 1275-82
43. Lane JS, Whang EE, Rigberg DA, et al. Paracellular glucose transport plays a minor role in the unanesthetized dog. Am J Physiol 1999; 276 (3 Pt 1): G789-94
44. He YL, Murby S, Warhurst G, et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci 1998; 87 (5): 626-33
45. Guengerich FP. Characterization of human cytochrome P450 enzymes. FASEB J 1992; 6 (2): 745-8
46. Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981; 19 (4): 271-8
47. Edgar B, Regardh CG, Johnsson G, et al. Felodipine kinetics in healthy men. Clin Pharmacol Ther 1985; 38 (2): 205-11
48. Kleinbloesem CH, van Brummelen P, van de Linde JA, et al. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984; 35 (6): 742-9
49. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24 (6): 472-95
50. Roberts CJ. Clinical pharmacokinetics of ranitidine. Clin Pharmacokinet 1984; 9 (3): 211-21
51. Gerkin R, Curry SC, Vance MV, et al. First-order elimination kinetics following baclofen overdose. Ann Emerg Med 1986; 15 (7): 843-6
52. Manley HJ, Bailie GR, McClaran ML, et al. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int 2003; 63 (3): 1072-8
53. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977; 12 (4): 297-303
54. Barnwell SG, Laudanski T, Story MJ, et al. Improved oral bioavailability of propranolol in healthy human volunteers using a liver bypass drug delivery system containing oleic acid. Int J Pharm 1992; 88: 423-32
55. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270 (1): 414-23
56. Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 'pie'. Drug Metab Dispos 2006; 34 (5): 880-6
57. Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80 (4): 1029-36
58. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283 (3): 1552-62
59. Yang J, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther 2004; 76 (4): 391
60. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338 (8781): 1488-90
61. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60 (1): 14-24
62. von Richter O, Greiner B, Fromm MF, et al. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther 2001; 70 (3): 217-27
63. Lasker JM, Wester MR, Aramsombatdee E, et al. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 1998; 353 (1): 16-28
64. Galetin A, Houston JB. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 2006; 318 (3): 1220-9
65. Zhang QY, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999; 27 (7): 804-9
66. Peters WH, Kremers PG. Cytochromes P-450 in the intestinal mucosa of man. Biochem Pharmacol 1989; 38 (9): 1535-8
67. Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999; 51 (2): 135-58
68. Gibbs MA, Thummel KE, Shen DD, et al. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999; 27 (2): 180-7
69. Holtbecker N, Fromm MF, Kroemer HK, et al. The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. Drug Metab Dispos 1996; 24 (10): 1121-3
70. Fagerholm U. Prediction of human pharmacokinetics-gut-wall metabolism. J Pharm Pharmacol 2007; 59 (10): 1335-43
71. Yang J, Jamei M, Yeo KR, et al. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007; 8 (7): 676-84
72. Van de Waterbeemd H. From in vivo to in vitro/in silico ADME: progress and challenges. Expert Opin Drug Metab Toxicol 2005; 1 (1): 1-4
73. Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 2005; 1 (1): 159-68
74. Willmann S, Schmitt W, Keldenich J, et al. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004; 47 (16): 4022-31
75. Grass GM. Simulation models to predict oral drug absorption from in vitro data. Adv Drug Deliv Rev 1997; 23: 199-219
76. Butina D, Segall MD, Frankcombe K. Predicting ADME properties in silico: methods and models. Drug Discov Today 2002; 7 Suppl. 11: S83-8
77. Grass GM, Sinko PJ. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 2002; 54 (3): 433-51
78. Norris DA, Leesman GD, Sinko PJ, et al. Development of predictive pharmacokinetic simulation models for drug discovery. J Control Release 2000; 65 (1-2): 55-62
79. Obata K, Sugano K, Saitoh R, et al. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int J Pharm 2005; 293 (1-2): 183-92
80. Dickens M, van de Waterbeemd H. Simulation models for drug disposition and drug interactions. Drug Discov Today Biosilico 2004; 2 (1): 38-45
81. Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007; 34 (3): 401-31
82. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 Suppl. 1: S41-67
83. Yu LX, Amidon GL. Characterization of small intestinal transit time distribution in humans. Int J Pharm 1998; 171: 157-63
84. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999; 186 (2): 119-25
85. De Buck SS, Sinha VK, Fenu LA, et al. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35 (10): 1766-80
86. Parrott N, Lave T. Prediction of intestinal absorption: comparative assessment of GastroPlus and Idea. Eur J Pharm Sci 2002; 17 (1-2): 51-61
87. Kuentz M, Nick S, Parrott N, et al. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 2006; 27 (1): 91-9
88. Jones HM, Parrott N, Ohlenbusch G, et al. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin Pharmacokinet 2006; 45 (12): 1213-26
89. Schmitt W, Willmann S. Physiology-based pharmacokinetic modeling: ready to be used. Drug Discov Today Technologies 2005; 2 (1): 125-32
90. Willmann S, Lippert J, Sevestre M, et al. PK-Sim® : a physiologically based pharmacokinetic 'whole-body' model. Biosilico 2003; 1 (4): 121-4
91. Kleine-Besten M, Willmann S, Edginton AN, et al. The prediction of cimetidine absorption profiles with PK-SIM® using in vitro dissolution data. German Chapter Annual Meeting of the Controlled Release Society; 2006 February 23-24; Jena
92. Jantratid E, Prakongpan S, Amidon GL, et al. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin Pharmacokinet 2006; 45 (4): 385-99
93. Blank K, Becker C, Lippert J, et al. Physiology-based models to simulate gut wall metabolism of nifedipine. DPhG Jahrestagung; 2007 October 10-13; Erlangen
94. Blank K, Becker C, Jantratid E, et al. PBPK modelling to demonstrate the impact of variability in CYP3A-mediated metabolism of nifedipine in different subpopulations. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; 2008 April 7-10; Barcelona
95. Bode H, Brendel E, Ahr G, et al. Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur J Clin Pharmacol 1996; 50 (3): 195-201
96. Guengerich FP, Martin MV, Beaune PH, et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261 (11): 5051-60